加载中
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
前收盘价
US$0.9586
+US$0.0427 · +4.66%
盘前
US$0.985
+US$0.0264 · +2.75%
10月8日 4:19 ET
盘中时间采用ET。市场数据可能有所延迟。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日内区间
当前US$0.9586
52周区间
当前US$0.9586
盘中时间采用ET。市场数据可能有所延迟。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日内区间
当前US$0.9586
52周区间
当前US$0.9586
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 2566.29万 USD | 4822.48万 USD | 2945.87万 USD | 4730.61万 USD | 4493.65万 USD |
| 销售、一般及管理费用 | 960.24万 USD | 1189.22万 USD | 1333.54万 USD | 1537.39万 USD | 1128.3万 USD |
| 营业费用 | 3526.52万 USD | 6011.7万 USD | 4279.41万 USD | 6268万 USD | 5621.95万 USD |
| 利息收入 | 332.39万 USD | 619.18万 USD | 732.3万 USD | 234.94万 USD | 18.54万 USD |
| 利息支出 | 190.53万 USD | 192.62万 USD | 207.1万 USD | 169.41万 USD | 174.21万 USD |
| 折旧和摊销 | 25.2万 USD | 24.96万 USD | 26.28万 USD | 25.87万 USD | 26.42万 USD |
| 营业利润 | −3526.52万 USD | −6011.7万 USD | −4279.41万 USD | −6268万 USD | −5621.95万 USD |
| 净利润 | −3384.67万 USD | −5585.14万 USD | −3754.25万 USD | −6202.46万 USD | −5777.63万 USD |
公司数据更新于 2026年10月8日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI264.1万0.00%2.3万亿 USD0.03%US$381.03-0.40%
Vanguard Extended Market ETFVXF84.9万0.00%954亿 USD0.05%US$233.49-1.56%
Vanguard Health Care ETFVHT24.79万0.00%220亿 USD0.09%US$315.31+0.78%
iShares Micro-Cap ETFIWC17.17万0.01%13.33亿 USD0.60%US$183.36-1.09%
Invesco RAFI US 1500 Small-Mid ETFPRFZ9.43万0.00%26.84亿 USD0.36%US$52.73-1.20%
Invesco NASDAQ Future Gen 200 ETFQQQS7.42万0.32%2296.09万 USD0.20%US$42.026-1.20%
Dimensional - US Small Cap ETFDFAS3.65万0.00%336.6亿 USD0.31%US$77.92-1.38%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
